Acesulfame

Summary

Acesulfame (CHEMBL176687) is a phase-3 clinical-stage small-molecule sweetening agent targeting TAS2R31 and TAS2R43.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 2 (TAS2R31, TAS2R43)
• Clinical trials: 2
• Chemistry: 163.15 Da · C4H5NO4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL176687
Name	Acesulfame
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	36573
ChEBI	CHEBI:83501
Molecular formula	C4H5NO4S
Molecular weight	163.15
InChIKey	YGCFIWIQZPHFLU-UHFFFAOYSA-N

SMILES: CC1=CC(=O)NS(=O)(=O)O1

IUPAC name: 6-methyl-2,2-dioxooxathiazin-4-one

ChEBI definition: A sulfamate ester that is 1,2,3-oxathiazin-4(3H)-one 2,2-dioxide substituted by a methyl group at position 6.

Pharmacological roles (ChEBI): sweetening agent.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Acesulfame, Acesulfamo, Acesulfame potassium, ACESULFAME POTASSIUM, ACESULFAME

Parent form; salt/anhydrous children: CHEMBL1351474

Patent coverage: 12,673 distinct patent families (37,157 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 37,147 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TAS2R31	TAS2R31	Agonist	2.6	0%	P59538
TAS2R43	TAS2R43	Agonist	2.51	0.9%	P59537

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Carbonic anhydrase 9.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CA9	5.62	Ki	2400	nM	CHEMBL_ACT_18407153

Target pathways

Aggregated over 2 target gene(s): TAS2R31, TAS2R43.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	2	TAS2R31, TAS2R43
Signaling by GPCR	2	TAS2R31, TAS2R43
GPCR downstream signalling	2	TAS2R31, TAS2R43
G alpha (i) signalling events	2	TAS2R31, TAS2R43
Class C/3 (Metabotropic glutamate/pheromone receptors)	2	TAS2R31, TAS2R43
GPCR ligand binding	2	TAS2R31, TAS2R43
Sensory Perception	2	TAS2R31, TAS2R43
Sensory perception of taste	2	TAS2R31, TAS2R43
Sensory perception of sweet, bitter, and umami (glutamate) taste	2	TAS2R31, TAS2R43

Dominant GO biological processes

GO term	Targets
detection of chemical stimulus involved in sensory perception of bitter taste	2
signal transduction	2
G protein-coupled receptor signaling pathway	2
sensory perception of taste	2

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03954418	Not specified	COMPLETED	Transport of Artificial Sweeteners During Pregnancy
NCT05671965	Not specified	COMPLETED	Effects of Oral Xylitol on Subsequent Energy Intake

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

1 molecules share ≥1 primary target. Top 1 by shared-target count:

Molecule	Source	Status	Shared targets
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	TAS2R31, TAS2R43